FundraiseJun 30, 2026, 07:24 UTC

Artivila lands $12.8M Series A to push AI drug discovery toward IPO

What's the deal? Shenzhen-based Artivila Biopharma has closed a Series A round of over $12.8 million for its AI-driven drug discovery platform.

Green Pine Capital Partners led the round, with Wider Link Enterprise Investment Limited and others joining.

The clinical-stage biotech has now raised more than $55 million in total funding.

Why now? Artivila plans to use the cash to advance IND filings for lead candidates and expand its pipeline ahead of a planned IPO.

It also wants to deepen partnerships with multinational pharma firms and grow its international footprint.

The company's lead asset, a dual-target IRAK4/1 inhibitor called ARD-885 for autoimmune disease, has posted Phase 1 data the firm describes as strong.

What could go wrong? Clinical-stage biotechs face long, costly trials, and early Phase 1 results rarely guarantee approval.

An IPO also depends on market conditions that can shift fast, leaving capital-hungry drug developers exposed.

The signal: The Dealroom data offers little to corroborate beyond broad investor profiles, with Green Pine's lead backer logged as an investment fund and the co-investor as a corporate vehicle. With ARD-885's early Phase 1 data in hand and IND filings on the horizon, Artivila's pitch to public markets will hinge on proving its AI platform shortens the path from target to clinic faster than rivals.